Genomics informatic — Quality control metrics for DNA sequencing
Introduction: The rapid progress in Next Generation Sequencing (NGS) technology has drastically reduced the cost and time for genomic analysis. A number of research institutions, corporations, and government agencies are competitively collecting a large volume of genomic data through multi-national, multi- institutional projects such as “DiscovEHR”[9], “gnomAD”[10] and “UK Biobank”[11]. The demand for sharing of “high quality” genomic data is growing because large-scale reference data is required for reliable detection of mutation for both industrial and clinical applications. However, the quality of available genomic data is less than desirable. To establish consistent quality control metrics, details of each stage of NGS process need to be recorded, shared and standardized (processes and data elements collected and coded for each stage and sub-stage). These processes include sample preparation, library preparation, sequencing, and data processing, among others, as shown in Figure 1. Figure 1 — NGS process vi © ISO 2020 – All rights reserved
Scope: This document identifies quality metrics for the detection of DNA variants using next generation sequencing (NGS) technology. It also defines the data types, relationships, optionality, cardinalities and terminology bindings of the data. This document provides a basis for sharing and for the application of “high quality” genomic data and contributes to the realization of the precision medicine and the development of relevant industries. This document is intended to serve as a catalogue of sequencing data elements used to address quality metrics for various clinical, industrial and commercial applications. The exchange of these data allows researchers, commercial entities, and regulatory bodies to assess for the purpose of selective utilization of the data by setting application-specific quality criteria This document is not intended for — sequencing methods other than NGS, such as the Sanger sequencing, — targets other than genome, such as transcriptome or proteome, or — specimens of species other than humans.